Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Gordon Kenneth B.; Foley Peter; Krueger James G.; Pinter Andreas; Reich Kristian; Vender Ronald; Vanvoorden Veerle; Madden Cynthia; White Katy; Cioffi Christopher; Blauvelt Andrew

首页> 外文期刊>The Lancet >Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

【24h】

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

机译：Bimekizumab疗效和安全性中度至重度斑块的牛皮癣（准备就绪）：多期，双盲，安慰剂控制，随机戒断第3阶段试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.

机译：背景：Bimekizumab是一种单克隆IgG1抗体，除IL-17A外，还可选择性抑制白细胞介素（IL）-17F。本研究调查了比美珠单抗在中重度斑块型银屑病患者中的疗效和安全性，停药的效果，以及56周内的两种维持给药方案。

著录项

来源
《The Lancet》 |2021年第10273期|共12页
作者
Gordon Kenneth B.; Foley Peter; Krueger James G.; Pinter Andreas; Reich Kristian; Vender Ronald; Vanvoorden Veerle; Madden Cynthia; White Katy; Cioffi Christopher; Blauvelt Andrew;
展开▼
作者单位

Med Coll Wisconsin Dept Dermatol Milwaukee WI 53226 USA;

Skin Hlth Inst Carlton Vic Australia;

Rockefeller Univ 1230 York Ave New York NY 10021 USA;

Univ Hosp Frankfurt Main Dept Dermatol Frankfurt Germany;

Univ Med Ctr Hamburg Eppendorf Inst Hlth Serv Res Dermatol &

Nursing Ctr Translat Res;

McMaster Univ Div Dermatol Hamilton ON Canada;

UCB Pharma Brussels Belgium;

UCB Pharma Raleigh NC USA;

UCB Pharma Slough Berks England;

UCB Pharma Raleigh NC USA;

Oregon Med Res Ctr Portland OR USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind,placebo-controlled multicenter trial [J] . YANG Hai-zhen, LIU Xiao-ming, TU Cai-xia, 中华医学杂志（英文版） . 2012,第011期
2. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021) [J] . Gordon K. B., Foley P., Krueger J. G. The Lancet . 2021,第10280期

机译：Bimekizumab疗效和安全性中度至重度斑块牛皮癣（准备好）：多期，双盲，安慰剂控制，随机撤离第3阶段试验（第397 Vol 397，PG 475,2021）
3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [J] . Reich Kristian, Papp Kim A., Blauvelt Andrew, The Lancet . 2021,第10273期

机译：Bimekizumab与Ustekinumab用于治疗中度至重度斑块的牛皮癣（生动）：52周，多期，双盲，活跃比较器和安慰剂控制第3阶段试验的功效和安全性
4. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021) [J] . Reich K., Papp K. A., Blauvelt A. The Lancet . 2021,第10275期

机译：Bimekizumab与Ustekinumab用于治疗中度至重度斑块的牛皮癣（生动）：52周，多方面，双盲，活跃的比较器和安慰剂控制第3阶段试验的功效和安全性（Vol 397，PG 487,2021）
5. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
6. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
7. A Phase IIIb Multicentre Randomised Parallel-Group Placebo-Controlled Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee [O] . Jozef Vojtaššák, Jozef Vojtaššák, Adam Jacobs, 2011

机译：IIIb期多中心随机平行组安慰剂对照双盲研究旨在研究OROS氢吗啡酮在中度至重度由髋或膝骨关节炎引起的中度至重度慢性疼痛患者中的疗效和安全性
8. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal [O] . K Gordon, P Foley, JG Krueger, 2020

机译：Bimekizumab在中度至重度斑块牛皮癣患者中的功效和安全性：准备好的结果，56周第3期，随机戒断的随机分配，双盲，安慰剂对照研究
9. Randontized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travelers' Diarrhea in US Military Personnel Deployed to lncirlik Air Base, lncirlik, Turkey [R] . Armstrong, A. W., Ulukan, S., Weiner, M., 2010

机译：Randontized，双盲，安慰剂对照研究评估利福昔明预防美国军人中的旅行者腹泻的功效和安全性，部署到土耳其lncirlik的lncirlik空军基地

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅